Literature DB >> 8393354

Demonstration of Epstein-Barr virus replication in Reed-Sternberg cells of Hodgkin's disease.

P Brousset1, H Knecht, B Rubin, E Drouet, S Chittal, F Meggetto, T A Saati, E Bachmann, G Denoyel, A Sergeant.   

Abstract

Epstein-Barr virus (EBV) is detectable in approximately 40% of cases of Hodgkin's disease (HD). The viral genomes remain latent but positive staining with anti-ZEBRA antibody in a small fraction of Reed-Sternberg (RS) cells of some cases of HD would suggest possible activation of EBV replication within these cells. We report the investigation of 40 cases of EBV-associated HD (including 5 human immunodeficiency virus [HIV]-positive cases) using anti-ZEBRA antibodies. Positive staining was found in only three (HIV-negative) cases. One of these three cases showed approximately 1% of ZEBRA-positive tumor cells, whereas the other two cases showed rare positive cells. In the case with 1% ZEBRA-positive cells, a strong signal was obtained with anti-EA-R antibody and BHLF1 oligoprobes, which indicated early gene expression. EBV replication could be shown in this case by nonisotopic in situ DNA-DNA hybridization, which showed markedly increased numbers of EBV genomes in a few RS cells. Viral replication was confirmed using reverse transcriptase and polymerase chain reaction that detected transcripts from the BLLF1 gene encoding for the membrane antigen gp350/220. EBV replication in RS cells seems to be an exceptional event but may provide clues to mechanisms of control of viral latency and assume clinical implications in the future.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8393354

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Expression of two related viral early genes in Epstein-Barr virus-associated tumors.

Authors:  S A Xue; Q L Lu; R Poulsom; L Karran; M D Jones; B E Griffin
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

2.  Sequential use of paraformaldehyde and methanol as optimal conditions for the direct quantification of ZEBRA and rta antigens by flow cytometry.

Authors:  B M Imbert-Marcille; M Coste-Burel; N Robillard; J Foucaud-Gamen; S Billaudel; E Drouet
Journal:  Clin Diagn Lab Immunol       Date:  2000-03

3.  The BFRF1 gene of Epstein-Barr virus encodes a novel protein.

Authors:  A Farina; R Santarelli; R Gonnella; R Bei; R Muraro; G Cardinali; S Uccini; G Ragona; L Frati; A Faggioni; A Angeloni
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

4.  Serum IgA to Epstein-Barr virus early antigen-diffuse identifies Hodgkin's lymphoma.

Authors:  Shane C McAllister; Duane Shedd; Nancy E Mueller; Ellen T Chang; George Miller; Sumita Bhaduri-McIntosh
Journal:  J Med Virol       Date:  2013-09-30       Impact factor: 2.327

5.  Reed-Sternberg cells and "bystander" lymphocytes in lymph nodes affected by Hodgkin's disease are infected with different strains of Epstein-Barr virus.

Authors:  F Meggetto; P Brousset; J Selves; G Delsol; B Mariame
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

Review 6.  Detection and characterization of Epstein-Barr virus in clinical specimens.

Authors:  R F Ambinder; R B Mann
Journal:  Am J Pathol       Date:  1994-08       Impact factor: 4.307

7.  Immunohistochemical detection of hepatitis C virus (genotype 4) in B-cell NHL in an Egyptian population: correlation with serum HCV-RNA.

Authors:  Iman Gouda; Ola Nada; Sameera Ezzat; Mai Eldaly; Christopher Loffredo; Clive Taylor; Mohamed Abdel-Hamid
Journal:  Appl Immunohistochem Mol Morphol       Date:  2010-01

8.  Epstein-Barr virus expression in Hodgkin's disease in relation to patient characteristics, serum factors and blood lymphocyte function.

Authors:  U Axdorph; A Porwit-MacDonald; J Sjöberg; G Grimfors; M Ekman; W Wang; P Biberfeld; M Björkholm
Journal:  Br J Cancer       Date:  1999-12       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.